Misonix to Present at the 43rd Annual Deutsche Bank Health Care Conference on May 8

FARMINGDALE, N.Y., April 23, 2018 — Misonix, Inc. (NASDAQ:MSON) (“Misonix” or the “Company”), a provider of minimally invasive therapeutic ultrasonic medical devices that enhance clinical outcomes, today announced that it will be participating in the Deutsche Bank 43rd Annual Health Care Conference held at the Intercontinental Hotel in Boston, Massachusetts on Tuesday, May 8, 2018. Misonix President and Chief Executive Officer, Stavros Vizirgianakis, will be making a company presentation at 1:30 p.m. ET that day followed by a question and answer session.

Mr. Vizirgianakis, along with Joe Dwyer, Misonix Chief Financial Officer, will be available to meet with institutional investors in one-on-one meetings throughout the day.

The Misonix investor presentation is available in the “Investor Relations” section of the Company’s website at www.misonix.com. If you have questions about Misonix or are interested in conducting a conference call or meeting with management, please contact the Company’s investor relations firm, JCIR, at (212) 835-8500 or via email at mson@jcir.com.

About Misonix, Inc.
Misonix, Inc. (NASDAQ:MSON) designs, develops, manufactures and markets ultrasonic medical devices for the precise removal of hard and soft tissue, including bone removal, wound debridement and ultrasonic aspiration. Misonix is focused on leveraging its proprietary ultrasonic technology to become the standard of care in operating rooms and clinics around the world. Misonix’s proprietary ultrasonic medical devices are used in a growing number of medical procedures, including spine surgery, neurosurgery, orthopedic surgery, cosmetic surgery, laparoscopic surgery, and other surgical and medical applications. At Misonix, Better Matters to us. That is why throughout the Company’s 59-year history, Misonix has maintained its commitment to medical technology innovation and the development of ultrasonic surgical products that radically improve patient outcomes. Additional information is available on the Company’s web site at www.misonix.com.

Joe Dwyer Joseph Jaffoni, Norberto Aja, Jennifer Neuman
Chief Financial Officer JCIR
Misonix, Inc. 212-835-8500 or mson@jcir.com


MiMedx to Highlight Efficacy of Its Allografts in Presentations at SAWC Spring Conference

MARIETTA, Ga.April 23, 2018 /PRNewswire/ — MiMedx Group, Inc. (NASDAQ: MDXG), a leading developer and marketer of regenerative and therapeutic biologics, today announced the Company’s participation in the 2018 Symposium on Advanced Wound Care Spring | Wound Healing Society (SAWC Spring/WHS) meeting being held April 25-29, 2018 in Charlotte, North Carolina.

During the five-day conference, the clinical and cost-effective healing results of the Company’s allografts will be highlighted in a Breakfast Symposium, two dinner presentations, five clinical poster presentations, and in-booth education sessions. MiMedx will be exhibiting in booth #830 from April 26, 2018 through April 28, 2018.

Now in its 31st year, the SAWC Spring/WHS conference is the leading national wound healing forum connecting the foremost experts with your entire wound care team to improve patient outcomes through education.  No other wound care conference offers the level of education, advanced state-of-the-art clinical reviews and emerging research findings.

MiMedx will sponsor a Breakfast Symposium entitled “EpiFix® – First and Only Amnion/Chorion Allograft with Statistically Significant Level I Evidence for healing in DFUs and VLUs” on Friday morning, April 27, 2018 from 7:30 am to 9:00 am. The Company will also host two dinner presentations on Thursday, April 26th and Friday, April 27th entitled “Using MiMedx Placental Tissues in the Lower Extremity“, which will review the use of various products in wound and surgical applications.

Hands-on product demonstrations will be provided by expert physicians during booth hours on April 26th and April 27thin the MiMedx booth.

The poster presentations will report on the clinical effectiveness of MiMedx EpiFix dHACM (dehydrated Human Amnion/Chorion Membrane) placental tissue allografts in the healing of diabetic foot ulcers, venous leg ulcers, pressure ulcers and refractory non-healing wounds, as well as the use of AmnioCord umbilical cord allografts for reducing Achilles tendon pain. These independent case studies and respective conclusions will include:

  • Abstract: “EpiFix VLU Study Group: A Multicenter Randomized Controlled Trial Evaluating the Efficacy of Dehydrated Human Amnion/Chorion Membrane Allograft for the Treatment of Venous Leg Ulcers
    Authors: Christian Bianchi, MD, FACS; Shawn Cazzell, DPM, FACFAS; Dean Vayser, DPM, FACFAS; Alexander M. Reyzelman, DPM, FACFAS; Hasan Dosluoglu, MD, FACS; Gregory Tovmassian, DPM
  • Abstract: “EpiFix DFU Study Group: A Confirmatory Study on the Efficacy of Dehydrated Human Amnion/Chorion Membrane (dHACM) Allograft in the Management of Diabetic Foot Ulcers: A Prospective, Multicenter, Randomized, Controlled Study
    Authors: William Tettelbach, MD; Shawn Cazzell, DPM; Alexander M. Reyzelman, DPM; Felix Sigal, DPM; Joseph M. Caporusso, DPM; Patrick S. Agnew, DPM
  • Abstract: “The Application of Dehydrated Human Amnion Chorion Membrane dHACM Allografts to Expedite Healing in Patients with Six Major Types of Refractory Non-Healing Wounds, 157 Patients
    Authors: Aamir Mahmood, DPM; Justin Goldsmith, DPM; Anna Tien, DPM; Mike Czurylo, DPM; Laith Shaman, DPM; Kelda Beachy, DPM; Neal Patel, DPM; Shayan Alamgir, DPM; Matthew Garoufalis, DPM, FASPS, FACFAOM
  • Abstract: “Use of Umbilical Cord Allograft for Pain Reduction in Achilles Tendon Pathologies: A Case
    Authors: Brandon Brooks, DPM; Kevin Pham, DPM; Bradley Brooks, DO; Brady Brooks, MS-1; James Henry, MS-1; Terria Madison, DPM
  • Abstract: “Safety and Efficacy of Weekly Application of Dehydrated Human Amnion/Chorion Membrane in the Treatment of Pressure Ulcers: a Case Series
    Authors: Chi Chi Berhane, MD, MBA; Kimberly Brantley, BSN, RN, CRRN; Sandra Williams, NP-C, APN, WCN; Erica Sutton, MACarlyn Kappy, RD, LD, CCRP

“For more than 30 years, SAWC and WHS have been dedicated to continuous advancements in wound care and have worked tirelessly toward their goal of decreasing the number and severity of wounds of all types.” said Parker H. “Pete” Petit, MiMedx Chairman and CEO. “We are honored to be a part of this year’s meeting, and MiMedx will continue to work with SAWC and other organizations to raise the level of scientific and clinical expertise and the professional processes within the wound care sector of healthcare.”

Bill Taylor, President and COO of MiMedx, added, “We are pleased that our EpiFix, AmnioCord and AmnioFill allografts will be so prominently demonstrated at this year’s SAWC. We look forward to participating in the conference and highlighting the significant investments made in the science and clinical study of placental technology.”

About MiMedx

MiMedx® is a leading biopharmaceutical company developing and marketing regenerative and therapeutic biologics utilizing human placental tissue allografts with patent-protected processes for multiple sectors of healthcare. “Innovations in Regenerative Medicine” is the framework behind the Company’s mission to give physicians products and tissues to help the body heal itself.  The Company processes the human placental tissue utilizing its proprietary PURION® Process methodology, among other processes, to produce safe and effective allografts by employing aseptic processing techniques in addition to terminal sterilization. MiMedx has supplied over 1 million allografts to date for application in the Wound Care, Burn, Surgical, Orthopedic, Spine, Sports Medicine, Ophthalmic and Dental sectors of healthcare. For additional information, please visit www.mimedx.com.


SOURCE MiMedx Group, Inc.

Related Links


Arthrosurface Gains FDA Clearance of OVOMotion™ Shoulder Arthroplasty System

FRANKLIN, Mass.April 18, 2018 /PRNewswire/ — Arthrosurface® announced today that The Company received FDA 510(k) Clearance to market the OVOMotion™ Shoulder Arthroplasty System. This stemless total shoulder system provides the surgeon with an approach that results in increased exposure to the glenoid, minimizes bone removal, and is designed for patients with painful and/or severely disabled shoulder joints resulting from arthritis, traumatic events or AVN.

“This truly is a revolutionary stemless total shoulder, which combines the concept of anatomic restoration with an aspherical head design that more closely replicates patient anatomy but also allows improved joint access for ease of preparation of the glenoid,” said Dr. Anthony Miniaci, MD.

The OVOMotion™ Shoulder Arthroplasty System is cleared for use in conjunction with the novel Arthrosurface Inlay Glenoid System and according to a comparative study published in the Journal of Shoulder and Elbow Surgery, the inlay glenoid (socket) design was far superior to the onlay alternative with respect to the biomechanical stability.

Steve Ek, CEO said, “The OVOMotion™ Shoulder Arthroplasty System is intended to be the first of a three-element modular stemless system that will ultimately allow surgeons to intra-operatively choose between stemless, traditional and reverse options.”

About Arthrosurface
Arthrosurface, Inc. is a global orthopedic medical technology business providing a broad portfolio of essential products and instrumentation used to treat upper and lower extremity orthopedic conditions caused by trauma, injury and arthritic disease. The product offerings include joint preservation implants, instruments and orthobiologics. Founded in 2002, Arthrosurface markets and distributes its products in the US and around the world and has succeeded in helping patients return to activity for over 14 years. For more information, please visit our website at www.arthrosurface.com

SOURCE Arthrosurface, Inc.

Related Links


SeaSpine to Report First Quarter 2018 Financial Results on May 3, 2018

CARLSBAD, Calif., April 19, 2018 (GLOBE NEWSWIRE) — SeaSpine Holdings Corporation (NASDAQ:SPNE), a global medical technology company focused on surgical solutions for the treatment of spinal disorders, announced today that it will release first quarter 2018 financial results after the close of trading on Thursday, May 3, 2018. The Company’s management team will host a conference call beginning at 1:30pm PT / 4:30pm ET to discuss the financial results and recent business developments.

Individuals interested in listening to the conference call may do so by dialing (877) 418-4766 for domestic callers or (614) 385-1253 for international callers, using Conference ID: 8167947. To listen to a live webcast, please visit the Investors section of the SeaSpine website at: www.seaspine.com.

The call will be archived until Thursday May 17, 2018. The audio archive can be accessed by calling (855) 859-2056 in the U.S. or (404) 537-3406 from outside the U.S. The passcode for the audio replay is 8167947.

About SeaSpine

SeaSpine is a global medical technology company focused on the design, development and commercialization of surgical solutions for the treatment of patients suffering from spinal disorders. SeaSpine has a comprehensive portfolio of orthobiologics and spinal implants solutions to meet the varying combinations of products that neurosurgeons and orthopedic spine surgeons need to perform fusion procedures on the lumbar, thoracic and cervical spine. SeaSpine’s orthobiologics products consist of a broad range of advanced and traditional bone graft substitutes that are designed to improve bone fusion rates following a wide range of orthopedic surgeries, including spine, hip, and extremities procedures. SeaSpine’s spinal implants portfolio consists of an extensive line of products to facilitate spinal fusion in minimally invasive surgery, complex spine, deformity and degenerative procedures. Expertise in both orthobiologic sciences and spinal implants product development allows SeaSpine to offer its surgeon customers a differentiated portfolio and a complete procedural solution to meet their fusion requirements. SeaSpine currently markets its products in the United States and in over 30 countries worldwide.

Investor Relations Contact
Lynn Pieper
(415) 937-5402

“Patch” May Help Recovery After Shoulder Surgery for Rotator Cuffs

Shoulder injury? Get “patched up” – literally, says renowned orthopedic surgeon and sports medicine and arthroplasty specialist, Kevin D. Plancher, MD, who is using advanced technology – an all-natural, biologic “patch” about the size of a postage stamp – to repair and heal a certain type of tendon tear in the rotator cuff.

“We find that patients with the patch recover successfully from surgery, and require less time to rehabilitate the injured shoulder, even those patients with diabetes and whom are overweight,” states Dr. Plancher, who founded New York and Connecticut-based Plancher Orthopaedics & Sports Medicine.

This patch helps resolve partial tears of rotator cuff tendons seen in many pro athletes and “weekend warriors”. It can also help large tears caused by injury or by the degeneration of shoulder tissue due to age,” Dr. Plancher says.

Developed by Rotation Medical, Inc., now distributed by Smith & Nephew, it is a “bio-inductive implant.” The patch is composed of collagen fibers from the Achilles tendons of bovine animals, including cows and sheep. Applied to the injured tendon arthroscopically with special instruments, the patch appears to foster new tissue growth that thickens and strengthens the tendon. Eventually, the implant “dissolves” and is absorbed by the body. The federal Food and Drug Administration cleared the way for the implant’s use in 2014.

Researchers are hoping this implant will be the “breakthrough” in rotator cuff repair, Dr. Plancher says. Initial clinical data involving 200 patients and presented at the May 2017 meeting of the Arthroscopy Association of North America indicated that use of the patch resulted in statistically significant improvement in overall shoulder function and pain following surgery. Patch patients generally reported feeling better in the first six months following their procedure than did patients who had undergone more traditional rotator cuff treatments after two years.

“As orthopedic surgeons, we have been searching for a new ‘gold standard’ – that would transform our approach to rotator cuff repair,” Dr. Plancher says. “Most perplexing has been the risk of an injured shoulder tendon re-tearing, actually pulling away from its sutures, in cases of large tears when the tendon has to be affixed to the bone.

Dr. Plancher’s enthusiasm is well founded. Rotator cuff injuries are common with approximately 4 million Americans suffering from a rotator cuff disorder, either due to injury or age, and more than 50 percent of those older than age 60 reportedly have some degree of rotator cuff tear.

The rotator cuff consists of a stabilizing system of four major tendons and muscles that keep the head of the upper arm bone in the shoulder socket, allowing the arm to be raised and rotated. Partial — or complete — tears of these tendons can occur from normal wear over time; repetitive use as occurs in certain sports, such as baseball or tennis, or in occupations like painting or carpentry; and even injury from falls or heavy lifting.

Symptoms of rotator cuff problems include a dull ache in the shoulder, arm weakness, difficulty in lifting or rotating an arm and disturbed sleep. Partial tendon tears, seen in many athletes can affect their careers and can degenerate and often become full thickness tears.

Of course, the best medicine is prevention. To minimize risk of rotator cuff injury, Dr. Plancher advises:

  •     Exercise regularly to keep muscles strong and flexible in and around the shoulder blades and on the backs of shoulders.
  •     Warm up muscles before engaging in sports and other vigorous activities.
  •     Avoid lifting – or trying to catch – large, heavy objects.
  •     Don’t keep arms raised or out from the side for long periods of time. If you must do so, take breaks and put a cold compress on the stressed shoulder several times daily.

Most importantly, if you have any of the above mentioned symptoms for a prolonged period of time make sure you seek medical attention from a fellowship trained shoulder surgeon.

Kevin D. Plancher, MD, MPH, is a board-certified orthopaedic shoulder surgeon, pioneer of shoulder procedures and the founder of Plancher Orthopaedics & Sports Medicine.

Plancher Orthopaedics & Sports Medicine is a comprehensive orthopaedics and sports medicine practice with offices in New York City and Greenwich, CT. http://www.plancherortho.com

RTI Surgical Schedules First Quarter 2018 Earnings Call for May 3, 2018

April 19, 2018

ALACHUA, Fla.–(BUSINESS WIRE)–RTI Surgical, Inc. (Nasdaq: RTIX), a global surgical implant company, today announced that it plans to release financial results for the first quarter 2018 on Thursday, May 3, 2018 prior to the market open.

RTI will host a conference call and simultaneous audio webcast to discuss first quarter results at 9:00 a.m. ET the same day. The conference call can be accessed by dialing (877) 383-7419 (U.S.) or (760) 666-3754 (International). The webcast can be accessed through the investor section of RTI’s website at www.rtix.com. A replay of the conference call will be available on RTI’s website for one month following the call.

About RTI Surgical, Inc.

RTI Surgical is a leading global surgical implant company providing surgeons with safe biologic, metal and synthetic implants. Committed to delivering a higher standard, RTI’s implants are used in sports medicine, general surgery, spine, orthopedic and trauma procedures and are distributed in nearly 50 countries. RTI has four manufacturing facilities throughout the U.S. and Europe. RTI is accredited in the U.S. by the American Association of Tissue Banks and is a member of AdvaMed. For more information, please visit www.rtix.com.

Forward-Looking Statements

This communication contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. These forward-looking statements are based on management’s current expectations, estimates and projections about our industry, our management’s beliefs and certain assumptions made by our management. Words such as “anticipates,” “expects,” “intends,” “plans,” “believes,” “seeks,” “estimates,” variations of such words and similar expressions are intended to identify such forward-looking statements. In addition, except for historical information, any statements made in this communication about anticipated financial results, growth rates, new product introductions, future operational improvements, gaining market share and results or regulatory actions or approvals or changes to agreements with distributors also are forward-looking statements. These statements are not guarantees of future performance and are subject to risks and uncertainties, including the risks described in public filings with the U.S. Securities and Exchange Commission (SEC). Our actual results may differ materially from the anticipated results reflected in these forward-looking statements. Copies of the company’s SEC filings may be obtained by contacting the company or the SEC or by visiting RTI’s website at www.rtix.com or the SEC’s website at www.sec.gov.


RTI Surgical, Inc.
Media Contact:
Molly Poarch, +1-224-287-2661
Investor Contact:
Nathan Elwell, +1-847-530-0249


Spikes of Graphene Can Kill Bacteria on Knee & Hip Implants

By Chalmers University of Technology – 04.16.18

A tiny layer of graphene flakes becomes a deadly weapon and kills bacteria, stopping infections during procedures such as implant surgery. This is the findings of new research from Chalmers University of Technology, Sweden, recently published in the scientific journal Advanced Materials Interfaces.

Operations for surgical implants, such as hip and knee replacements or dental implants, have increased in recent years. However, in such procedures, there is always a risk of bacterial infection. In the worst-case scenario, this can cause the implant to not attach to the skeleton, meaning it must be removed.

Bacteria travel around in fluids, such as blood, looking for a surface to cling on to. Once in place, they start to grow and propagate, forming a protective layer, known as a biofilm.

A research team at Chalmers has now shown that a layer of vertical graphene flakes forms a protective surface that makes it impossible for bacteria to attach. Instead, bacteria are sliced apart by the sharp graphene flakes and killed. Coating implants with a layer of graphene flakes can therefore help protect the patient against infection, eliminate the need for antibiotic treatment, and reduce the risk of implant rejection. The osseointegration—the process by which the bone structure grow to attach the implant—is not disturbed. In fact, the graphene has been shown to benefit the bone cells.

Chalmers University is a leader in the area of graphene research, but the biological applications did not begin to materialise until a few years ago. The researchers saw conflicting results in earlier studies. Some showed that graphene damaged the bacteria, others that they were not affected.

“We discovered that the key parameter is to orient the graphene vertically. If it is horizontal, the bacteria are not harmed” said Ivan Mijakovic, Professor at the Department of Biology and Biological Engineering.




SpineGuard® Announces First Spinal Deformity Surgery in China with PediGuard® by Prof. Yong Qiu

April 18, 2018


SpineGuard (FR0011464452 – ALSGD), an innovative company that develops and markets instruments designed to secure the placement of surgical implants by bringing real-time digital technology into the operating room, announced today that Professor Yong QIU performed the first spinal deformity surgery in China with the PediGuard® device.

Pr. Yong QIU is the Chairman of Orthopedic Surgery at Nanjing Drum Tower Hospital, President of the Chinese Scoliosis Research Society, and Vice-President of the Chinese Association of Orthopedic Surgeons and one of the leading scoliosis surgeons in China. His spine center is the largest scoliosis center in China, performing around 600 scoliosis surgeries per year, the majority of which are among the most complex cases in China.

This surgery case demonstrates the ability of XinRong Medical to quickly bring to market PediGuard enabled surgeries with the most preeminent surgeons in China, and highlights Xinrong’s ability to assist leading foreign brands in navigating the local tendering and hospital approval process.

“PediGuard increases safety for better screw placement, reduces surgical time by 15%, decreases X-ray exposure for patients, surgeons and staff and also helps train the young surgeons. It is a very useful and convenient device that is effective without any other supplementary equipment for complex spine surgery, especially for spinal deformity cases,” said Professor Yong Qiu, Chairman of Orthopedic Surgery of Nanjing Drum Tower Hospital.

“It is an immense honor for SpineGuard that Professor Yong Qiu performed the first spinal deformity surgery in China with the PediGuard device to secure pedicle screw placement. Professor Yong Qiu, who was trained in France, is the most experienced surgeon for spinal deformity in China with over 3,000 spinal deformity surgeries to his credit,” added Patricia Lempereur, International Director of Sales and Marketing at SpineGuard.

“We are honored by the use of PediGuard for spinal deformity cases at the Nanjing Drum Tower Hospital, one of the world most famous hospitals for spinal deformity with over 9,000 cases since their opening. We look forward to extending our collaboration with Pr. Yong Qiu with the use of PediGuard technology in training junior surgeons in China for pedicular screw placementChina market is growing rapidly, with spine surgery cases expected to grow around in the mid double digits in next 5 years. XinRong covers 2600 hospitals in China. We have great confidence that with the wide application PediGuard by Chinese surgeons will continue to dramatically enhance surgery case outcomes,” concluded Christine Zhang, XinRong Medical Group’s CEO.

The event was also reported by Chinese television news program, watch here.

More information on the DSG® technology and surgeons’ testimonials here.

Next financial press release: 2018 Half-year revenue: July 11, 2018

About SpineGuard®

Founded in 2009 in France and the USA by Pierre Jérôme and Stéphane Bette, SpineGuard’s mission is to make spine surgery safer by bringing real-time digital technology into the operating room. Its primary objective is to establish its proprietary DSG™ (Dynamic Surgical Guidance) technology as the global standard of surgical care, starting with safer screw placement in spine surgery and then in other surgeries. PediGuard®, the first device designed using DSG, was co-invented by Maurice Bourlion, Ph.D., Ciaran Bolger, M.D., Ph.D., and Alain Vanquaethem, Biomedical Engineer. It is the world’s first and only handheld device capable of alerting surgeons to potential pedicular or vertebral breaches. Over 60,000 surgical procedures have been performed worldwide with DSG™ enabled devices. Numerous studies published in peer-reviewed medical and scientific journals have demonstrated the multiple benefits that PediGuard® delivers to patients, surgical staff and hospitals. SpineGuard is expanding the scope of its DSG™ platform through strategic partnerships with innovative medical device companies and the development of smart instruments and implants. SpineGuard has offices in San Francisco and Paris. For further information, visit www.spineguard.com.

About XinRong Medical Group

XinRong Medical Group, a leader in medical technology, is dedicated to increasing patient affordability and providing the most advanced solutions for surgeons such that they can deliver the best patient care. XinRong Medical offers innovative solutions in orthopedic surgery, neurosurgery, reconstructive surgery, and minimally invasive therapy. Established in 2000 in Jiangsu Province, China, XinRong Medical was one of the first companies in China cleared by CFDA to manufacture Orthopedic Implants. In 2014, the Company received a strategic investment from The Blackstone Group (NYSE: BX). For additional information about XinRong Medical, please refer to our website www.XRBest.Com, or contact us directly at +86-512-58100828 or info@xrmed.com.


The SpineGuard securities may not be offered or sold in the United States as they have not been and will not be registered under the Securities Act or any United States state securities laws, and SpineGuard does not intend to make a public offer of its securities in the United States. This is an announcement and not a prospectus, and the information contained herein does and shall not constitute an offer to sell or the solicitation of an offer to buy, nor shall there be any sale of the securities referred to herein in the United States in which such offer, solicitation or sale would be unlawful prior to registration or exemption from registration.


Stéphane Bette
Chief Executive Officer
Tel: +33 (0)1 45 18 45 19
Manuel Lanfossi
Chief Financial Officer
Europe / NewCap
Investor Relations & Financial Communication
Mathilde Bohin / Pierre Laurent
Tel: +33 (0)1 44 71 94 94

Histogenics Corporation Announces the Appointment of Susan Washer to Its Board of Directors

WALTHAM, Mass., April 18, 2018 (GLOBE NEWSWIRE) — Histogenics Corporation (Histogenics) (Nasdaq:HSGX), a leader in the development of restorative cell therapies (RCTs) that may offer rapid-onset pain relief and restored function, today announced the appointment of Susan Washer to its Board of Directors.

“Having known and worked with Sue for over 15 years, we are extremely pleased to welcome her to Histogenics’ Board of Directors,” stated Garheng Kong, M.D., Ph.D., Chairman of the Board of Directors of Histogenics.  “We believe Sue’s experience in the growing area of cell and gene therapies combined with her expertise in the development of novel gene therapies make her an excellent choice for the Histogenics Board of Directors.”

“The Histogenics restorative cell therapy platform and the NeoCart product opportunity are compelling for patients and clinicians, and I’m excited to be joining the Board of Directors,” noted Sue Washer, President & Chief Executive Officer of Applied Genetic Technologies Corporation (AGTC).  “I look forward to contributing to the growth of Histogenics as it prepares for potential FDA submissions and commercialization and continues to broaden its product platform both internationally and in other potential therapeutic applications.”

Ms. Washer is the President and Chief Executive Officer of AGTC, where she has served in such capacity since March 2002 and as a member of its board of directors since November 2003. Ms. Washer was also AGTC’s Chief Operating Officer from October 2001 to March 2002. From June 1994 to October 2001, Ms. Washer led two entrepreneurial firms including serving as president and CEO of Scenic Productions and as the Founding Executive Director and then Business Advisor for the North Florida Technology Innovation Center, a public-private organization financing and providing services to entrepreneurial companies licensing STEM based technology from Florida universities.  Ms. Washer currently serves on the board of directors of Biotechnology Innovation Organization (BIO) and the Alliance for Regenerative Medicine. Previously, Ms. Washer served as chairman of the BioFlorida board and the Southeast BIO board and continues her involvement with both organizations as a member of their respective boards.

From October 1983 to June 1994, Ms. Washer served in various research and pharmaceutical management positions with Abbott Laboratories and Eli Lilly and Company. Ms. Washer received a B.S. in biochemistry from Michigan State University and an M.B.A. from the University of Florida.

About Histogenics Corporation

Histogenics (Nasdaq:HSGX) is a leader in the development of restorative cell therapies that may offer rapid-onset pain relief and restored function. Histogenics’ lead investigational product, NeoCart, is designed to rebuild a patient’s own knee cartilage to treat pain at the source and potentially prevent a patient’s progression to osteoarthritis. NeoCart is one of the most rigorously studied restorative cell therapies for orthopedic use. Histogenics recently completed enrollment of its NeoCart Phase 3 clinical trial and expects to report top-line, one-year superiority data in the third quarter of 2018. NeoCart is designed to perform like articular hyaline cartilage at the time of treatment, and as a result, may provide patients with more rapid pain relief and accelerated recovery as compared to the current standard of care. Histogenics’ technology platform has the potential to be used for a broad range of additional restorative cell therapy indications. For more information on Histogenics and NeoCart, please visit www.histogenics.com.

First Case for Augmented Shoulder Baseplate

By: Elizabeth Hofheinz, M.P.H., M.Ed., April 17, 2018

Zimmer Biomet Holdings, Inc., based in Warsaw, Indiana, has announced that the first surgical case utilizing its Comprehensive Augmented Baseplate was performed by John W. Sperling, M.D., an orthopedic surgeon at Mayo Clinic.

According to the company, “This newly cleared baseplate boasts a simplified circular design at three augment heights (3mm, 5mm and 7mm buildup), allowing for augment placement in any orientation to accommodate various unique bone anatomies. Its circular design also allows bone ingrowth into the rim of the baseplate for optimal fixation.”

“The Comprehensive Augmented Baseplate is a component of the Comprehensive Reverse Shoulder System, a next-generation reverse shoulder prosthesis engineered to offer high-quality intraoperative flexibility and clinically proven technologies.”

“The system aims to minimize the potential challenges of removing well-fixed humeral stems by allowing conversion to a reverse shoulder using any of the existing Comprehensive stems. Additionally, the Comprehensive Augmented Baseplate leverages Mayo Clinic’s patented methodology for the optimization of shoulder arthroplasty components developed by Dr. Sperling at Mayo Clinic, Rochester, Minn., to provide relevant sizing for a conservative approach to bone removal to preserve bone stock if a future revision procedure is necessary.”